These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37533228)

  • 1. Genomic alterations of oligodendrogliomas at distant recurrence.
    Liu G; Bu C; Guo G; Zhang Z; Sheng Z; Deng K; Wu S; Xu S; Bu Y; Gao Y; Wang M; Liu G; Kong L; Li T; Li M; Bu X
    Cancer Med; 2023 Aug; 12(16):17171-17183. PubMed ID: 37533228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and epigenetic stability of oligodendrogliomas at recurrence.
    Aihara K; Mukasa A; Nagae G; Nomura M; Yamamoto S; Ueda H; Tatsuno K; Shibahara J; Takahashi M; Momose T; Tanaka S; Takayanagi S; Yanagisawa S; Nejo T; Takahashi S; Omata M; Otani R; Saito K; Narita Y; Nagane M; Nishikawa R; Ueki K; Aburatani H; Saito N
    Acta Neuropathol Commun; 2017 Mar; 5(1):18. PubMed ID: 28270234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.
    Cahill DP; Louis DN; Cairncross JG
    CNS Oncol; 2015; 4(5):287-94. PubMed ID: 26545048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.
    Yip S; Butterfield YS; Morozova O; Chittaranjan S; Blough MD; An J; Birol I; Chesnelong C; Chiu R; Chuah E; Corbett R; Docking R; Firme M; Hirst M; Jackman S; Karsan A; Li H; Louis DN; Maslova A; Moore R; Moradian A; Mungall KL; Perizzolo M; Qian J; Roldan G; Smith EE; Tamura-Wells J; Thiessen N; Varhol R; Weiss S; Wu W; Young S; Zhao Y; Mungall AJ; Jones SJ; Morin GB; Chan JA; Cairncross JG; Marra MA
    J Pathol; 2012 Jan; 226(1):7-16. PubMed ID: 22072542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ETV/Pea3 family transcription factor-encoding genes are overexpressed in CIC-mutant oligodendrogliomas.
    Padul V; Epari S; Moiyadi A; Shetty P; Shirsat NV
    Genes Chromosomes Cancer; 2015 Dec; 54(12):725-33. PubMed ID: 26357005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.
    Tateishi K; Nakamura T; Juratli TA; Williams EA; Matsushita Y; Miyake S; Nishi M; Miller JJ; Tummala SS; Fink AL; Lelic N; Koerner MVA; Miyake Y; Sasame J; Fujimoto K; Tanaka T; Minamimoto R; Matsunaga S; Mukaihara S; Shuto T; Taguchi H; Udaka N; Murata H; Ryo A; Yamanaka S; Curry WT; Dias-Santagata D; Yamamoto T; Ichimura K; Batchelor TT; Chi AS; Iafrate AJ; Wakimoto H; Cahill DP
    Clin Cancer Res; 2019 Jul; 25(14):4375-4387. PubMed ID: 30975663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH-Mutant Astrocytoma With Chromosome 19q13 Deletion Manifesting as an Oligodendroglioma-Like Morphology.
    Miyake Y; Fujii K; Nakamaura T; Ikegaya N; Matsushita Y; Gobayashi Y; Iwashita H; Udaka N; Kumagai J; Murata H; Takemoto Y; Yamanaka S; Ichimura K; Tateishi K; Yamamoto T
    J Neuropathol Exp Neurol; 2021 Feb; 80(3):247-253. PubMed ID: 33432322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted.
    Yasuda T; Nitta M; Komori T; Kobayashi T; Masui K; Maruyama T; Sawada T; Muragaki Y; Kawamata T
    Neuropathology; 2018 Feb; 38(1):41-46. PubMed ID: 28812310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors.
    Chan AK; Pang JC; Chung NY; Li KK; Poon WS; Chan DT; Shi Z; Chen L; Zhou L; Ng HK
    Mod Pathol; 2014 Mar; 27(3):332-42. PubMed ID: 24030748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.
    Thomas AA; Abrey LE; Terziev R; Raizer J; Martinez NL; Forsyth P; Paleologos N; Matasar M; Sauter CS; Moskowitz C; Nimer SD; DeAngelis LM; Kaley T; Grimm S; Louis DN; Cairncross JG; Panageas KS; Briggs S; Faivre G; Mohile NA; Mehta J; Jonsson P; Chakravarty D; Gao J; Schultz N; Brennan CW; Huse JT; Omuro A
    Neuro Oncol; 2017 Oct; 19(10):1380-1390. PubMed ID: 28472509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report.
    Ono T; Reinhardt A; Takahashi M; Nanjo H; Kamataki A; von Deimling A; Shimizu H
    Acta Neurochir (Wien); 2020 Dec; 162(12):3019-3024. PubMed ID: 32785787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.
    Back M; Jayamanne D; Brazier D; Newey A; Bailey D; Schembri G; Hsiao E; Khasraw M; Wong M; Kastelan M; Brown C; Wheeler H
    Strahlenther Onkol; 2020 Jan; 196(1):31-39. PubMed ID: 31028406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
    van den Bent MJ; Dubbink HJ; Marie Y; Brandes AA; Taphoorn MJ; Wesseling P; Frenay M; Tijssen CC; Lacombe D; Idbaih A; van Marion R; Kros JM; Dinjens WN; Gorlia T; Sanson M
    Clin Cancer Res; 2010 Mar; 16(5):1597-604. PubMed ID: 20160062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases.
    Kanamori M; Kumabe T; Shibahara I; Saito R; Yamashita Y; Sonoda Y; Suzuki H; Watanabe M; Tominaga T
    Brain Tumor Pathol; 2013 Jul; 30(3):151-9. PubMed ID: 23053495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligodendrogliomas: new insights from the genetics and perspectives.
    Alentorn A; Sanson M; Idbaih A
    Curr Opin Oncol; 2012 Nov; 24(6):687-93. PubMed ID: 22913971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and clonal evolution
    Liu G; Bu C; Guo G; Zhang Z; Sheng Z; Deng K; Wu S; Xu S; Bu Y; Gao Y; Wang M; Liu G; Kong L; Li T; Li M; Bu X
    iScience; 2023 Sep; 26(9):107528. PubMed ID: 37649695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens.
    Pallavajjala A; Haley L; Stinnett V; Adams E; Pallavajjala R; Huang J; Morsberger L; Hardy M; Long P; Gocke CD; Eshleman JR; Rodriguez FJ; Zou YS
    Hum Pathol; 2022 Aug; 126():63-76. PubMed ID: 35561840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
    Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
    Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.
    Sahm F; Koelsche C; Meyer J; Pusch S; Lindenberg K; Mueller W; Herold-Mende C; von Deimling A; Hartmann C
    Acta Neuropathol; 2012 Jun; 123(6):853-60. PubMed ID: 22588899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas.
    Lazow MA; Hoffman L; Schafer A; Osorio DS; Boué DR; Rush S; Wright E; Lane A; DeWire-Schottmiller MD; Smolarek T; Sipple J; Taggert H; Reuss J; Salloum R; Hummel TR; de Blank P; Pillay-Smiley N; Sutton ME; Asher A; Stevenson CB; Drissi R; Finlay JL; Fouladi M; Fuller C
    Acta Neuropathol Commun; 2020 Nov; 8(1):182. PubMed ID: 33153497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.